RS66214B1 - Kokristali (1r,3s)-3-(5-cijano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentan karboksilne kiseline - Google Patents
Kokristali (1r,3s)-3-(5-cijano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentan karboksilne kiselineInfo
- Publication number
- RS66214B1 RS66214B1 RS20241203A RSP20241203A RS66214B1 RS 66214 B1 RS66214 B1 RS 66214B1 RS 20241203 A RS20241203 A RS 20241203A RS P20241203 A RSP20241203 A RS P20241203A RS 66214 B1 RS66214 B1 RS 66214B1
- Authority
- RS
- Serbia
- Prior art keywords
- crystal
- cyano
- ylcarbamoyl
- thiazol
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/02—Salts; Complexes; Addition compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382194.7A EP3882240A1 (en) | 2020-03-16 | 2020-03-16 | Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcabamoyl)cyclopentane carboxylic acid |
| EP21710531.1A EP4121419B1 (en) | 2020-03-16 | 2021-03-15 | Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid |
| PCT/EP2021/056506 WO2021185748A1 (en) | 2020-03-16 | 2021-03-15 | Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcabamoyl)cyclopentane carboxylic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS66214B1 true RS66214B1 (sr) | 2024-12-31 |
Family
ID=69953938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20241203A RS66214B1 (sr) | 2020-03-16 | 2021-03-15 | Kokristali (1r,3s)-3-(5-cijano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentan karboksilne kiseline |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12384754B2 (https=) |
| EP (2) | EP3882240A1 (https=) |
| JP (1) | JP7779846B2 (https=) |
| KR (1) | KR20220154791A (https=) |
| CN (1) | CN115298169B (https=) |
| AU (1) | AU2021237686B2 (https=) |
| BR (1) | BR112022018449A2 (https=) |
| CA (1) | CA3171894C (https=) |
| DK (1) | DK4121419T3 (https=) |
| ES (1) | ES3002084T3 (https=) |
| FI (1) | FI4121419T3 (https=) |
| HR (1) | HRP20241515T1 (https=) |
| HU (1) | HUE068886T2 (https=) |
| LT (1) | LT4121419T (https=) |
| MX (1) | MX2022011530A (https=) |
| PL (1) | PL4121419T3 (https=) |
| PT (1) | PT4121419T (https=) |
| RS (1) | RS66214B1 (https=) |
| SI (1) | SI4121419T1 (https=) |
| WO (1) | WO2021185748A1 (https=) |
| ZA (1) | ZA202211247B (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2331220B1 (es) | 2007-10-02 | 2010-09-23 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina. |
| US8779146B2 (en) | 2010-04-28 | 2014-07-15 | Nuformix Limited | Cilostazol cocrystals and compositions |
| LT3592734T (lt) | 2017-03-06 | 2021-07-26 | Palobiofarma, S.L. | (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksirūgšties amino druska |
-
2020
- 2020-03-16 EP EP20382194.7A patent/EP3882240A1/en not_active Withdrawn
-
2021
- 2021-03-15 CN CN202180021708.3A patent/CN115298169B/zh active Active
- 2021-03-15 EP EP21710531.1A patent/EP4121419B1/en active Active
- 2021-03-15 PT PT217105311T patent/PT4121419T/pt unknown
- 2021-03-15 MX MX2022011530A patent/MX2022011530A/es unknown
- 2021-03-15 HR HRP20241515TT patent/HRP20241515T1/hr unknown
- 2021-03-15 ES ES21710531T patent/ES3002084T3/es active Active
- 2021-03-15 AU AU2021237686A patent/AU2021237686B2/en active Active
- 2021-03-15 BR BR112022018449A patent/BR112022018449A2/pt unknown
- 2021-03-15 RS RS20241203A patent/RS66214B1/sr unknown
- 2021-03-15 CA CA3171894A patent/CA3171894C/en active Active
- 2021-03-15 HU HUE21710531A patent/HUE068886T2/hu unknown
- 2021-03-15 WO PCT/EP2021/056506 patent/WO2021185748A1/en not_active Ceased
- 2021-03-15 DK DK21710531.1T patent/DK4121419T3/da active
- 2021-03-15 US US17/906,367 patent/US12384754B2/en active Active
- 2021-03-15 KR KR1020227035871A patent/KR20220154791A/ko active Pending
- 2021-03-15 LT LTEPPCT/EP2021/056506T patent/LT4121419T/lt unknown
- 2021-03-15 SI SI202130224T patent/SI4121419T1/sl unknown
- 2021-03-15 PL PL21710531.1T patent/PL4121419T3/pl unknown
- 2021-03-15 FI FIEP21710531.1T patent/FI4121419T3/fi active
- 2021-03-15 JP JP2022555805A patent/JP7779846B2/ja active Active
-
2022
- 2022-10-13 ZA ZA2022/11247A patent/ZA202211247B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES3002084T3 (en) | 2025-03-06 |
| JP7779846B2 (ja) | 2025-12-03 |
| KR20220154791A (ko) | 2022-11-22 |
| MX2022011530A (es) | 2022-10-13 |
| HUE068886T2 (hu) | 2025-02-28 |
| EP4121419A1 (en) | 2023-01-25 |
| CN115298169A (zh) | 2022-11-04 |
| FI4121419T3 (fi) | 2024-11-04 |
| US12384754B2 (en) | 2025-08-12 |
| LT4121419T (lt) | 2024-11-25 |
| CA3171894C (en) | 2025-03-11 |
| EP3882240A1 (en) | 2021-09-22 |
| WO2021185748A1 (en) | 2021-09-23 |
| CN115298169B (zh) | 2024-11-19 |
| US20230183195A1 (en) | 2023-06-15 |
| DK4121419T3 (da) | 2024-10-28 |
| ZA202211247B (en) | 2023-12-20 |
| AU2021237686A1 (en) | 2022-10-06 |
| BR112022018449A2 (pt) | 2022-11-01 |
| AU2021237686B2 (en) | 2026-04-09 |
| HRP20241515T1 (hr) | 2025-01-03 |
| PL4121419T3 (pl) | 2025-02-17 |
| CA3171894A1 (en) | 2021-09-23 |
| EP4121419B1 (en) | 2024-08-14 |
| PT4121419T (pt) | 2024-11-18 |
| SI4121419T1 (sl) | 2025-02-28 |
| JP2023517722A (ja) | 2023-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102445601B1 (ko) | 엘로빅시바트의 결정수식 | |
| HUE028620T2 (en) | Tetrahydroisoquinoline derivative salt and solvates | |
| HUE026408T2 (en) | Dabigatran etexylate bis-mesylate salt, solid forms and process for their preparation | |
| US12319652B2 (en) | Salts and solid forms of (R)-1-(5-methoxy-1H-indol-1-yl)-N,N-dimethylpropan-2-amine | |
| AU2014336929B2 (en) | Salt and crystal forms of PLK-4 inhibitor | |
| JP7561497B2 (ja) | 結晶性ピリミジニル-3,8-ジアザビシクロ[3.2.1]オクタニルメタノン化合物およびその使用 | |
| WO2013139195A1 (zh) | 石杉碱甲多晶型体、其制备方法、包含所述多晶型体的药物组合物及其用途 | |
| JP6827124B2 (ja) | (1r,3s)−3−(5−シアノ−4−フェニル−1,3−チアゾール−2−イルカルバモイル)シクロペンタンカルボン酸のアミン塩 | |
| AU2021237686B2 (en) | Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid | |
| EA045045B1 (ru) | Сокристаллы (1r,3s)-3-(5-циано-4-фенил-1,3-тиазол-2-илкарбамоил)циклоопентанкарбоновой кислоты | |
| KR20140022851A (ko) | 오타믹사반의 벤조산염 | |
| WO2025228973A1 (en) | Cocrystals of n-{cis-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide | |
| RU2599789C2 (ru) | Новая полиморфная форма кальцимиметического соединения | |
| HK40020652B (en) | Amine salt of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl) cyclopentane carboxylic acid | |
| HK40020652A (en) | Amine salt of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl) cyclopentane carboxylic acid | |
| KR20250065875A (ko) | 네피카스타트 산 부가 염의 다형체 형태, 이의 제조 방법 및 이의 용도 | |
| CN101115706A (zh) | 制备普伐他汀钠的方法 |